Survivor Spotlight: Tom Lauritzen, Stage III Survivor
…melanoma journey when he had a large melanoma removed from his back. It was almost an inch in diameter. Curiously,…
Survivor Spotlight: Tom Lauritzen, Stage III Survivor
…melanoma journey when he had a large melanoma removed from his back. It was almost an inch in diameter. Curiously,…
,
Vaccines 2021—Major Advances in Preventing Death from Infection and Malignancy
…and initial studies in melanoma have shown great promise for these types of vaccine, which are based on the patient’s…
,
,
Val Guild Honored at 2022 ASCO Annual Conference
…The group organized an evening in her honor at the Ritz Carlton Chicago, and invited their fellow melanoma oncologists and…
,
Clinical Trials Catch Up
…that are funded by the National Cancer Institute in the U.S.—and there are about a dozen trials that either are…
,
Immunocore Presents Three-Year Overall Survival Data from the KIMMTRAK Phase 3 Trial
…survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial Presenting author: Sophie Piperno-Neumann Session: Mini oral session…
,
,
Bristol Myers Squibb Announces Approval for Subcutaneous Nivolumab
…treatment options in order to be active participants in treatment and care. AIM at Melanoma’s global research initiatives include The…
,
,
Genetic Test a Potential Alternative to Sentinel Lymph Node Biopsy
…genetics with the patient’s age and clinical features of the melanoma to assess whether a patient has a low or…
,
Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN®
…recognizing Merlin CP-GEP¹ (clinicopathologic–gene expression profile test) as the first and only molecular test that may be used in select early-stage melanoma patients.…
,
,
Why Peer Support is Important for People Coping With Melanoma
…Their large family keeps them happy and on the move! Bob is actively involved in AIM at Melanoma and other…
,
EXCLUSIVE WEBINAR: The FDA Approval of TIL Therapy and What it Means for Advanced Melanoma
An exciting new development in melanoma treatment is the recent FDA-approval of Lifileucel (AMTAVGI) therapy, which harnesses the power of…
,
Recent Posts
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026